Developing new treatments for tuberculosis

Know More
 

Fighting TB, a disease that kills more than 1.5 million people every year

Know More
 

A single product, multiple indications

Know More
 

A GMP Plant to offer specialized services to biotech industry

KNOW MORE

Archivel Farma is a R&D biotech company that develops immunotherapeutic agents to respond to unmet medical needs

Tuberculosis (TB) is the greatest killer worldwide due to a single infectious agent

One third of the world’s population is infected with Mycobacterium tuberculosis

RUTI® is the most promising therapeutic vaccine against TB out of 12 in development

One million children worldwide fell ill with tuberculosis in 2016

Mismanagement of treatment can produce multidrug-resistant TB

RUTI® is being evaluated to treat diseases such as asthma and allergic rhinitis

News

Archivel-Farma-Vilaplana-Cardona-Rue ArchivelPress release
06/12/2021

CONSTAN, a new clinical trial with the vaccine RUTI® to shorten the current treatment of tuberculosis

The RUTI® vaccine -developed by Archivel Farma- will be administered in the CONSTAN clinical trial, approved by the Spanish Agency of Medicines and Medical Devices (AEMPS), to validate its efficacy…
Albert Canals
0
STriTuVaD-Consortium-ArchivelFarma ArchivelGeneralPress release
22/10/2021

The STriTuVaD Consortium is proud to announce the recruitment of the First Patient in the STriTuVaD Clinical Trial of RUTI® Vaccine for Tuberculosis (TB)

The Spanish biotech company Archivel Farma has officially begun the clinical trial of its therapeutic vaccine RUTI®, which will be carried out by Clinical Research Network India, a Contract Research…
Albert Canals
0
ArchivelPress releaseResearch
08/04/2020

Archivel Farma’s RUTI® vaccine to start a clinical trial to increase the immunity of healthcare professionals exposed to the risk of COVID-19

The clinical trial will be carried out at the Germans Trias i Pujol Hospital in Badalona (Can RUTI), and it will include 300 healthy health professionals in direct contact with…
Albert Canals
2